Last reviewed · How we verify

NCT02673788

Follow-Up Study of Safety of Pneumostem® in Premature Infants With Intraventricular Hemorrhage

Status unknown Last updated 7 April 2019
What this trial tests

trial testing observation without intervention in this follow up study in Intracranial Hemorrhages in 9 participants. Status unknown.

Timeline
1 January 2016
Primary endpoint
1 December 2022
1 December 2023

Quick facts

Lead sponsorSamsung Medical Center
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment9
Start date1 January 2016
Primary completion1 December 2022
Estimated completion1 December 2023
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Samsung Medical Center

Who can join

Adults 6 Months to 2, any sex, with Intracranial Hemorrhages or Mesenchymal Stem Cells. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

This is a follow-up study of the open label, single-center, phase I clinical trial to evaluate the safety of Pneumostem® in premature infants with Intraventricular hemorrhage.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Mesenchymal Stem Cells for Severe Intraventricular Hemorrhage in Preterm Infants: Phase I Dose-Escalation Clinical Trial.
    Ahn SY, Chang YS, Sung SI, Park WS. · · 2018 · cited 117× · PMID 30133179 · DOI 10.1002/sctm.17-0219
  2. Perinatal Hyperoxia and Developmental Consequences on the Lung-Brain Axis.
    Obst S, Herz J, Alejandre Alcazar MA, Endesfelder S, et al · · 2022 · cited 37× · PMID 35251477 · DOI 10.1155/2022/5784146
  3. Opportunities in posthemorrhagic hydrocephalus research: outcomes of the Hydrocephalus Association Posthemorrhagic Hydrocephalus Workshop.
    Koschnitzky JE, Keep RF, Limbrick DD, McAllister JP, et al · · 2018 · cited 36× · PMID 29587767 · DOI 10.1186/s12987-018-0096-3
  4. Mesenchymal stem cells for the prevention and treatment of bronchopulmonary dysplasia in preterm infants.
    Pierro M, Thébaud B, Soll R. · · 2017 · cited 34× · PMID 29125893 · DOI 10.1002/14651858.cd011932.pub2
  5. The Potential of Mesenchymal Stromal Cell as Therapy in Neonatal Diseases.
    Liau LL, Al-Masawa ME, Koh B, Looi QH, et al · · 2020 · cited 32× · PMID 33251167 · DOI 10.3389/fped.2020.591693
  6. Posttraumatic hydrocephalus: Recent advances and new therapeutic strategies.
    Sanker V, Kundu M, El Kassem S, El Nouiri A, et al · · 2023 · cited 15× · PMID 38028696 · DOI 10.1002/hsr2.1713
  7. Prevention, Reduction and Repair of Brain Injury of the Preterm Infant.
    van Bel F, Vaes J, Groenendaal F. · · 2019 · cited 13× · PMID 30949060 · DOI 10.3389/fphys.2019.00181
  8. Stem cell-based interventions for the prevention and treatment of germinal matrix-intraventricular haemorrhage in preterm infants.
    Romantsik O, Bruschettini M, Moreira A, Thébaud B, et al · · 2019 · cited 7× · PMID 31549743 · DOI 10.1002/14651858.cd013201.pub2

Verify or expand the search:

Other recruiting trials for Intracranial Hemorrhages

Currently open trials in the same condition.

Other Samsung Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02673788.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing